XLV - ETF AI Analysis
Top Page
Health Care Select Sector SPDR Fund (XLV)
Rating:73Outperform
Price Target:―
Positive Factors
Strong Performance From Major Holdings
Several of the largest positions, including Eli Lilly, Johnson & Johnson, AbbVie, UnitedHealth, Merck, Amgen, and Gilead, have shown strong gains this year, helping support the ETF’s overall returns.
Low Expense Ratio
The fund charges a relatively low fee, which means more of the investment returns stay in investors’ pockets over time.
Consistent Recent Performance
The ETF has delivered steady gains over the past month, three months, and year to date, suggesting solid recent momentum in the health care sector.
Negative Factors
High Stock Concentration
A small group of companies, led by Eli Lilly and Johnson & Johnson, make up a large share of the portfolio, increasing the impact that problems at these firms could have on the fund.
Sector Concentration Risk
Almost all of the ETF’s assets are in health care, so it may be heavily affected by changes in regulation, drug pricing, or other industry-specific issues.
Limited Geographic Diversification
The fund is almost entirely invested in U.S. companies, offering little protection if the U.S. market or economy faces health care–related challenges.
XLV vs. SPDR S&P 500 ETF (SPY)
AUM43.37B
RegionNorth America
Expense Ratio0.08%
Beta0.41
IssuerSPDR
Inception DateDec 16, 1998
Dividend Yield1.5%
Asset ClassEquity
Index TrackedS&P Health Care Select Sector
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume6,955,608
30 Day Avg. Volume9,196,617
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
190.22Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering60
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XLV Summary
XLV is an exchange-traded fund that focuses on the U.S. healthcare sector by tracking the S&P Health Care Select Sector Index. It owns many large healthcare companies, including Johnson & Johnson and Pfizer, as well as drug makers, biotech firms, medical device companies, and health insurers. Investors might consider XLV for long-term growth and diversification, since healthcare is an essential service and tends to be more stable than some other industries. However, XLV is heavily concentrated in healthcare stocks, so its value can go up or down based on changes in healthcare policy, drug pricing, and the overall stock market.
How much will it cost me?The Health Care Select Sector SPDR Fund (XLV) has an expense ratio of 0.08%, meaning you’ll pay $0.80 per year for every $1,000 invested. This cost is lower than average because XLV is passively managed, tracking the Health Care Select Sector Index rather than relying on active stock picking.
What would affect this ETF?The XLV ETF, focused on the U.S. healthcare sector, could benefit from increasing demand for healthcare services driven by aging populations and advancements in medical technology. However, it may face challenges from regulatory changes, drug pricing pressures, or economic downturns that could impact healthcare spending. Its exposure to major companies like Johnson & Johnson and Pfizer provides stability but also ties its performance to the success of these key players.
XLV Top 10 Holdings
XLV is essentially a bet on big U.S. healthcare, with pharma and biotech heavyweights steering the ship. Merck and Amgen have been rising steadily, giving the fund a strong tailwind, while Johnson & Johnson and AbbVie add solid, if slightly more measured, momentum. Eli Lilly, despite its size, has seen more mixed action lately, losing a bit of steam and tempering gains. UnitedHealth and Abbott are contributing in a more uneven way, leaving XLV concentrated in a handful of large, U.S.-based drugmakers and health services giants.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 14.87% | $6.47B | $1.07T | 51.05% | 72 Outperform | |
| Johnson & Johnson | 10.64% | $4.63B | $644.12B | 55.16% | 78 Outperform | |
| AbbVie | 7.69% | $3.35B | $463.89B | 18.88% | 66 Neutral | |
| Merck & Company | 5.88% | $2.56B | $357.52B | 77.74% | 80 Outperform | |
| UnitedHealth | 5.65% | $2.46B | $336.83B | 12.06% | 72 Outperform | |
| Thermo Fisher | 3.94% | $1.72B | $239.76B | 36.84% | 72 Outperform | |
| Amgen | 3.36% | $1.46B | $203.47B | 36.44% | 77 Outperform | |
| Gilead Sciences | 3.01% | $1.31B | $183.12B | 31.55% | 78 Outperform | |
| Abbott Laboratories | 2.94% | $1.28B | $177.12B | -23.71% | 73 Outperform | |
| Pfizer | 2.60% | $1.13B | $156.51B | 14.45% | 74 Outperform |
XLV Technical Analysis
Positive
―
Price Trends
166.63
Positive
158.38
Positive
155.10
Positive
Market Momentum
0.02
Positive
51.07
Neutral
35.48
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XLV, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 170.49, equal to the 50-day MA of 166.63, and equal to the 200-day MA of 155.10, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 51.07 is Neutral, neither overbought nor oversold. The STOCH value of 35.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XLV.
XLV Peer Comparison
Comparison Results
Performance Comparison
XLV
Health Care Select Sector SPDR Fund
168.81
33.88
25.11%
VGT
Vanguard Information Technology ETF
―
―
―
XLK
Technology Select Sector SPDR Fund
―
―
―
VHT
Vanguard Health Care ETF
―
―
―
XBI
SPDR S&P BIOTECH ETF
―
―
―
IBB
iShares Biotechnology ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents